The clinical behaviour of gastrointestinal stromal tumours (GIST) is notoriously difficult to predict. The prognostic and therapeutic significance of KIT mutations is somewhat contradictory ([Ernst *et al*, 1998](#bib1){ref-type="other"}; [Lasota *et al*, 1999](#bib10){ref-type="other"}; [Moskaluk *et al*, 1999](#bib13){ref-type="other"}; [Taniguchi *et al*, 1999](#bib17){ref-type="other"}; [Lasota *et al*, 2000](#bib11){ref-type="other"}; [Hirota *et al*, 2001](#bib5){ref-type="other"}; [Wardelmann *et al*, 2002](#bib18){ref-type="other"}; [Koay *et al*, 2005](#bib6){ref-type="other"}). Therefore, it appears that new molecular indicators of prognostication are needed. Tissue microarrays (TMA) is a high-throughput method for the analysis of large numbers of formalin-fixed, paraffin-embedded (FFPE) materials with minimum cost and effort ([Kononen *et al*, 1998](#bib7){ref-type="other"}). Here, we applied the TMA technology to analyse protein expression in GIST. The results were analysed with an unsupervised, hierarchical monothetic cluster statistical method. Those biomarkers with strong clinical significance were tested for mutation status by both PCR-denaturing high performance liquid chromatography (DHPLC) and direct sequencing. By doing so, we identified a *VEGF-A protein overexpression signature* as a statistically significant predictor of malignancy, discovered *VEGF-A* ligand DNA variants in GIST, and provided other possible targets in future design of anti-VEGF-directed therapy against GIST.

MATERIALS AND METHODS
=====================

We used 50 archival paraffin blocks (Department of Pathology, National University Hospital, Singapore), including 15 cases of GIST with a benign outcome, 17 with a malignant outcome (13 primary neoplasms and four metastases), 10 with no available clinical follow-up, and eight gastrointestinal mesenchymal neoplasms other than GIST, such as leiomyoma (*n*=5), leiomyosarcoma, neurofibroma and schwannoma (one of each). The mean clinical follow-up was of 39 months. The overall clinico-pathological characteristics are summarised in [Table 3](#tbl3){ref-type="table"}. No chemo or radiotherapy was given to these patients. All the gross and histopathological parameters classically associated with malignant potential were analysed. The findings were similar to those reported in other series (data not shown) and, in themselves, are considered insufficient for single-case prognostication in the clinical setting.

After case review for diagnostic confirmation, the TMA was constructed as reported elsewhere ([Zhang *et al*, 2003a](#bib21){ref-type="other"}; [Salto-Tellez *et al*, 2004](#bib15){ref-type="other"}). The 22 antibodies used are 34 BE12, AE 1/3, Bcl-2, CAM 5.2, CD10, CD117, CD34, c-erbB2, CK7, CK20, Desmin, Flk-1, Flt-1, Hep Par1, Ki-67, MNF 116, p53, PCNA, S100, SMA, VEGF-A and Vimentin. [Table 4](#tbl4){ref-type="table"} indicates the antibodies and their technical specifications. In general, these antibodies can be divided into several groups: diagnostic markers, antibodies expressed in a specific differentiation pathway relevant to GIST, proliferative or apoptosis-related markers, angiogenic proteins, and others that may have been associated before with prognostic significance in GIST. The interpretation of the IHC staining results for TMA was confirmed by three independent observers (NME, LCK and MST). Results were interpreted based on previous published experience for each individual antibody.

The concordance between TMA and full sections, tested for five antibodies ([Table 5](#tbl5){ref-type="table"}) ranged from 92--100% in five of six antibodies, excluding S100 (71%), in concordance with previous published results ([Zhang *et al*, 2003a](#bib21){ref-type="other"}).

The 28 FFPE cases with available clinical follow-up were the subject of genomic DNA extraction (GENTRA DNA Purification Kit -- Gentra, Minneapolis, MN, USA), according to the manufacturer\'s instruction. Mutation analysis was performed by PCR-DHPLC analysis. Briefly, DNA was amplified in 25 *μ*l reactions containing 2 *μ*l DNA template, 1 *μ*l of each forward and reverse primers (10 *μ*[M]{.smallcaps} each), 0.5 *μ*l of 10 m[M]{.smallcaps} dNTP, 0.2 *μ*l FastStart Taq (Roche, Mannheim, Germany), and 1 × PCR reaction buffer with MgCl~2~. Primer sequences and cycling conditions are indicated in [Tables 6](#tbl6){ref-type="table"} and [7](#tbl7){ref-type="table"}. The PCR product (8 *μ*l) was denatured at 95°C for 5 min followed by gradual re-annealing to room temperature for over a period of 1 h. DHPLC was performed using a fully automated WAVE 3500HT system (Transgenomic, Omaha, NE, USA). The cooled samples were automatically injected into a DNASep cartridge (Transgenomic) and eluted at a flow rate of 0.9 ml min^−1^ through a linear gradient of acetonitrile containing 0.1 [M]{.smallcaps} triethylammonium acetate (TEAA). Buffer A (0.1 [M]{.smallcaps} TEAA solution) and buffer B (0.1 [M]{.smallcaps} TEAA with 25% acetonitrile solution) concentrations and oven temperatures for optimal heteroduplex separation under partially DNA denaturation was determined using the WAVE Navigator software followed by empirical adjustment. Amplicons from the HeLa cell line were included in each run as a wild-type reference.

Samples showing a dHPLC aberrant elution profile were re-amplified and sequenced in both directions. Direct sequencing was performed on the ABI PRISM Model 3100 DNA sequencer (Applied Biosystems, Foster City, CA, USA), using the same primers as were used for amplification. Sequencing reactions were conducted with the ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the manufacturer\'s instructions.

The monothetic cluster analysis was carried out as reported elsewhere ([Zhang *et al*, 2003b](#bib22){ref-type="other"}) Significance tests included the student\'s unpaired *t*-test (2-tailed) for numerical variables and the Fisher\'s exact probability test for categorical variables. Significance value for *P* was taken to be *P*\<0.05.

RESULTS
=======

VEGF protein expression signature and its prognostic significance in GIST
-------------------------------------------------------------------------

[Table 1](#tbl1){ref-type="table"} shows the whole protein expression results. [Figure 1](#fig1){ref-type="fig"} shows the cluster diagram obtained upon monothetic hierarchical cluster analysis, including IHC of representative cases. From the cluster analysis, two main groups emerged, based on reactivity for the VEGF-A ligand antibody. Group 1 includes all the VEGF-A ligand expressing cases; out of the 20 GISTs with known clinical outcome, 15 were malignant (75%). In group 2 (VEGF-A negative), only 2/11 of the cases (18%) had a malignant outcome. The difference was statistically significant (*P=*0.003). Within group 2, the two malignant cases are further subclassified into a cluster arm, which is positive for flt-1, a receptor for VEGF. Hence, all 17/17 malignant cases were positive for either VEGF-A ligand or the VEGF-A receptor, flt-1, as compared to 8/15 of the benign cases (*P=*0.002). In all, 13/17 malignant cases were positive for *both* these markers as compared to 4/15 benign cases (*P=*0.006). Indeed, concomitant expression of VEGF ligand and VEGF receptor represents a *VEGF-A protein expression signature* in GIST with obvious clinical significance. Lastly, proliferation and oncogenic-related markers PCNA, Ki-67/MIB, bcl-2 and p53 showed no statistically significant preference in reactivity for malignant GISTs (*P\>0.05*). The fact that all the smooth muscle lesions included in the analysis are clustering in a separate group (group 3) is a measure of the robustness of this analytical approach.

New VEGF-A variants are discovered as a result of mutation analysis
-------------------------------------------------------------------

Those GIST samples with known clinical follow-up underwent genomic analysis. In view of the evidence of *KIT* mutations in GIST and their possible prognostic value (as well as their relation to imatinib therapeutic response) ([Lasota *et al*, 1999](#bib10){ref-type="other"}; [Heinrich *et al*, 2003](#bib3){ref-type="other"}), exons 9, 11, 13, 17 of *KIT* (which are those related to prognosis in the literature) were analysed in the same methodological manner. The results are summarised in [Table 2](#tbl2){ref-type="table"}. Variants identified included non-coding IVS1--7:C → T changes in five (18%) samples ([Figure 2](#fig2){ref-type="fig"}), IVS4--28:C → T changes in seven (25%) samples and coding codon 48A:G → T (Q → H) and codon 91A:G → A (G → D) changes in one sample each ([Table 2](#tbl2){ref-type="table"}). A total of 12 (43%) cases had variants in *KIT*, all in exon 11 ([Figure 3](#fig3){ref-type="fig"}). *VEGF* IVS4--28:C → T variants were more frequent in samples with low (5/7, 71%) than high (2/7, 29%) VEGF-A expression. The *VEGF* codon 48 and 91 mutants were present in samples with high VEGF-A expression, *KIT* mutations and of a malignant phenotype. *KIT* mutations were more frequent in samples with high (10/22, 46%) than low (2/6, 21%) KIT expression. Nevertheless, none of the associations between sequence variants and the expression of their respective proteins, or with the presence of each other, were significant, presumably due to the limited number of samples in this series. The only parameter significantly associated with malignancy in these selected 28 cases was, as expected, VEGF-A protein expression (*P=*0.020). Of interest, there was no association with exon 11 *KIT* mutations and survival in our series.

DISCUSSION
==========

The uncertain prognosis of GIST, both before ([Nilsson *et al*, 2005](#bib14){ref-type="other"}) and after ([Kosmadakis *et al*, 2005](#bib8){ref-type="other"}) imatinib treatment, indicate the need for the search of other molecular prognostication biomarkers.

GIST are highly vascularised neoplasms and VEGF-A is a major antiangiogenic therapeutic target ([Ferrara and Kerbel, 2005](#bib2){ref-type="other"}). Recently, anti-VEGF-A therapy has been successful in the treatment of GIST ([Marx 2005](#bib12){ref-type="other"}), with drugs such as Sutent and Sorafenib. Our results indicate that a combined VEGF-A ligand-receptor protein expression signature is a determinant of clinical behaviour in GIST. This is obvious in our study because (a) there is a relation between protein overexpression of the VEGF-A ligand and Flt-1 proteins and benign/malignant behaviour; (b) novel variants in the *VEGF-A ligand* gene are characterised, some of which appear related to a malignant behaviour (such as *VEGF-A* exon 3); and (c) in general, these VEGF-ligand variants localise to areas of the VEGF protein with functional significance. The role of flt-1 in this context is unclear; it could be related to the induction of metalloproteinases ([Hiratsuka *et al*, 2002](#bib4){ref-type="other"}), or to chemotactic signals ([Wey *et al*, 2005](#bib19){ref-type="other"}).

The role of the detected VEGF-A ligand variants in protein overexpression and GIST tumorigenesis can only be a matter of speculation, based on the scant information available. The IVS4--28:C → T variant is also identified in phenotypically normal gastrointestinal tissue, thus may not be relevant. The two other variants, however, may have functional implications. The IVS1--7:C → T variant lies within a GC box that binds the transcriptional repressor protein methyl CpG binding protein-2 ([Lapchak *et al*, 2004](#bib9){ref-type="other"}), and was found to be associated with higher levels of VEGF mRNA in colorectal cancer ([Yamamori *et al*, 2004](#bib20){ref-type="other"}), increasing the risk of liver metastasis and worsening its prognosis. In addition, two missense mutations (unreported to date) were discovered in exon 3, coding codon 48A:G → T (Q → H) and codon 91A:G → A (G → D), both in malignant GIST and both showing VEGF-A ligand protein overexpression. In any case, the evidence points to the novel hypothesis that *VEGF-A* ligand mutations may play a role if the biology and prognosis of GIST.

There has been a previous suggestion that VEGF-A ligand protein expression may be related to prognosis ([Takahashi *et al*, 2003](#bib16){ref-type="other"}). However, the strength of our unsupervised hierarchical cluster analysis, comparing the expression of an antibody in the context of another 21 biomarkers, delineates 'biological groups\' and establishes more complete 'prognostic signatures\', which in our study, shown the importance of including protein expression of both VEGF-A ligand and flt-1 receptor in the characterisation of malignant behaviour.

![In red are the study cases with malignant behaviour, in blue are those cases with benign behaviour; cases without available follow-up and non-GISTs are in black. The TMA immunohistochemistry results are included. The asterisk indicates cases reflected in the photomicrographs. Other abbreviations are similar to those described in [Table 1](#tbl1){ref-type="table"}. VEGF1 is equivalent to VEGF-A in this figure.](6603551f1){#fig1}

![(**A**) DHPLC analysis of *VEGF-A* ligand exon 1: the mutant has an additional peak (indicated by the arrow) and shows a shift in elution time (indicated by the vertical hashed lines). (**B**) Sequencing chromatogram of *VEGF-A* ligand exon 1: direct sequencing indicated that the mutation in the sample is an IVS1 −7C\>T variant.](6603551f2){#fig2}

![(**A**) DHPLC analysis of *KIT* exon 11: the mutant has two additional peaks (indicated by the arrows) and shows a mild shift in elution time (indicated by the vertical hashed lines). (**B**) Sequencing chromatogram of *KIT* exon11: direct sequencing indicated that the mutation in the sample is a 27 bp deletion.](6603551f3){#fig3}

###### 

Indication of the immunohistochemistry results based on the groups from the hierarchical cluster analysis (see [Figure 1](#fig1){ref-type="fig"}), and highlighting the VEGF protein expression signature
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###### 

Protein expression and sequence status of VEGF and KIT in malignant and benign GIST samples

              **VEGF**   **KIT**   **VEGF**       **VEGF**         **VEGF**        **KIT**
  ----------- ---------- --------- -------------- ---------------- --------------- ---------------------
  benign                                                                            
  1           \+         \+                                                         
  2           \+         \+                                                        550A:deletion 27bp
  3           \+         \+        IVS1--7:C\>T                                     
  4           \+         \+                                                         
  5           −          \+                                        IVS4--28:C\>T   559C:deletion 6bp
  6           −          \+                                        IVS4--28:C\>T   572A: insertion 5bp
  7           −          \+                                        IVS4--28:C\>T    
  8           −          \+                                                        558A:deletion 9bp
  9           −          \+                                                         
  10          −          \+                                                         
  11          −          \+                                                         
  12          −          −         IVS1--7:C\>T                                     
  13          −          −                                         IVS4--28:C\>T    
                                                                                    
  malignant                                                                         
  1           \+         \+        IVS1--7:C\>T                                     
  2           \+         \+                       91A:G\>A(G\>D)                   557A:deletion 6bp
  3           \+         \+                                        IVS4--28:C\>T   550A:deletion 27bp
  4           \+         \+                                                        550A:deletion 27bp
  5           \+         \+                                                        557T:deletion 6bp
  6           \+         \+                                                        558G:deletion 3bp
  7           \+         \+                                                         
  8           \+         \+                                                         
  9           \+         \+                                                         
  10          \+         \+                                                         
  11          \+         −                                                          
  12          \+         −         IVS1--7:C\>T   48A:G\>T(Q\>H)   IVS4--28:C\>T   550A:deletion 27bp
  13          −          \+                                        IVS4--28:C\>T   550A:deletion 27bp
  14          −          −         IVS1--7:C\>T                                    551C:deletion 12bp
  15          −          −                                                          

+=expression, −=no expression.

Sequence variants are denoted as 'codon followed by nucleotide position (A=1st, B=2nd, C=3rd): nucleotide change (protein change)\'. Non-coding variants are denoted as 'IVS, exon, nucleotides from exon start: nucleotide change\'.

###### 

Characteristics of benign (B) and malignant (M) GISTs

  **No**    **Age**  **Site**        **Size (mm)**   **Cell type**   **Mitoses (/50 HPF)**   **SMA % +ve**   **CD34 % +ve**   **CD117 % +ve**   **Status (months)**  **Metastases/recurrence**
  -------- --------- -------------- --------------- --------------- ----------------------- --------------- ---------------- ----------------- --------------------- ---------------------------------------
  B1          45     Duod                 20               s                   2                   0               0                100              aned (76)       Nil
  B2          39     Gastric              70               m                  1.5                  0              100               80              aned (124)       Nil
  B3          45     Gastric              10               s                   0                   0              100               95               aned (24)       Nil
  B4          46     Gastric              27               s                   1                   0              100               100              aned (20)       Nil
  B5          53     Gastric              29               m                   0                   0               80               85               aned (24)       Nil
  B6          69     Gastric              35               s                   1                  10              100               40               aned (87)       Nil
  B7          71     Gastric              90               s                   1                   0              100               100              aned (3)        Nil
  B8          77     Gastric              45               s                   1                   0              100               80               aned (68)       Nil
  B9          42     Gastric              50               s                  3.5                  0               0                 0               aned (13)       Nil
  B10         50     Gastric              100              s                   1                   0               90               30               aned (10)       Nil
  B11         62     Gastric               6               s                   1                  15              100               100              aned (1)        Nil
  B12         87     Gastric              25               s                   0                   0              100               100              aned (6)        Nil
  B13         87     Gastric               7               s                   3                   0              100               100              aned (12)       Nil
  B14         47     Pelvic               60               s                   4                   0              100               100              aned (83)       Nil
  B15         49     Jejunal              45               s                   2                   0               0                100              aned (60)       Nil
  M1          67     Colon                90               s                  15                   0              100                0               dod (21)        LR
  M2          37     Duodenal             60               m                  4.5                  0               70               50               awd (89)        Liver
  M3          36     Gastric              180              s                 62.5                  0              100               100              dod (17)        Liver
  M4          52     Gastric              190              s                  7.5                  0              100               100              dod (36)        No data
  M5          59     Gastric              70               e                  10                   0               0                 0               dod (72)        Liver, bones, abdominal nodes
  M6          71     Gastric              170              e                  24                   0              100               100             awd (103).       Omentum, LR
  M7          41     Gastric              100              e                  26                   0              100               75               dod (43)        Retroperitoneum
  M8          48     Gastric              35               s                 24.5                  0              100               70               dod (27)        Peritoneum
  M9          48     Gastric              150              s                  31                   0              100               100              dod (22)        Liver, spleen
  M10         68     Gastric              110              s                 113.5                 0              100               85                dod (7)        Liver, LR
  M11         73     Gastric              60               s                 66.5                  0              100               100               dod (8)        No data
  M12         65     Jejuno-ileal         90               s                  52                  45              100               100              awd (15)        Peritoneum
  M13         33     Rectal               60               s                  0.5                 2.5             100               70                  duc          Liver, bone, para-aortic nodes, lungs

B=Benign cases; M=Malignant cases; s=spindle cell type; e epithelioid cell type; m=mixed epithelioid and spindle cell type; aned=alive with no evidence of disease; awd=alive with disease; dod=died of disease; duc=died of unrelated causes; LR=local recurrence.

###### 

Antibodies used

  **Antibody**   **Type**     **Source**                                       **Dilution**
  -------------- ------------ ----------------------------------------------- --------------
  34 BE12        Monoclonal   Dako, Glostrup, Denmark                             1:500
  AE 1/3         Monoclonal   Dako, Glostrup, Denmark                             1:1000
  Bcl-2          Monoclonal   Dako, Glostrup, Denmark                             1:200
  CAM 5.2        Monoclonal   Becton-Dickinson, San Jose, CA, USA                  1:20
  CD10           Monoclonal   Novocastra, Newcastle, UK                           1:200
  CD117          Polyclonal   Dako, Denmark                                       1:1000
  CD34           Monoclonal   Dako, Glostrup, Denmark                             1:1000
  c-erbB2        Monoclonal   Signet Laboratories Inc., Dedham, MA, USA           1:200
  CK7            Monoclonal   Dako, Glostrup, Denmark                             1:2000
  CK20           Monoclonal   Neomarker, Fremont, CA, USA                         1:200
  Desmin         Monoclonal   Neomarker, Fremont, CA, USA                         1:500
  Flk-1          Monoclonal   Santa Cruz Biotechnology, Santa Cruz, CA, USA       1:500
  Flt-1          Monoclonal   Santa Cruz Biotechnology, Santa Cruz, CA, USA       1:1000
  Hep Par1       Monoclonal   Dako, Glostrup, Denmark                             1:500
  Ki-67          Monoclonal   Dako, Glostrup, Denmark                             1:100
  MNF 116        Monoclonal   Dako, Glostrup, Denmark                             1:500
  p53            Monoclonal   Dako, Glostrup, Denmark                             1:500
  PCNA           Monoclonal   Dako, Glostrup, Denmark                             1:1000
  S100           Polyclonal   Dako, Glostrup, Denmark                            1:10 000
  SMA            Monoclonal   Dako, Glostrup, Denmark                             1:1000
  VEGF-A         Monoclonal   Santa Cruz Biotechnology, Santa Cruz, CA, USA       1:500
  Vimentin       Monoclonal   Dako, Glostrup, Denmark                             1:1000

###### 

Comparison of results of TMA *vs* full section analysis

                        **SMA**   **Vim**   **CAM5.2**   **CD117**   **CD34**   **S100**
  --------------- ---- --------- --------- ------------ ----------- ---------- ----------
  Full sections    \+     14        47          3           39          37         17
                   −      37         4          48          12          14         34
  TMA              \+     14        47          1           35          34         4
                   −      37         4          50          16          17         47
  Disagree         4       0         2          4            3          15          
  Concordance %    92     100       96          92          94          71          

###### 

*KIT* PCR conditions

  **Exon**   **Forward primer**          **Reverse primer**               **Size (bp)**   **Tm (°C)**   **DHPLC temperature (°C)**  **DHPLC gradient**
  ---------- --------------------------- ------------------------------- --------------- ------------- ---------------------------- -------------------------
  9          5′ATGCTCTGCTTCTGTACTGCC3′   ′CAGAGCCTAAACATCCCCTTA3′              185            60                    57              47.5--61.5%B in 4.5 min
  11         5′CCAGAGTGCTCTAATGACTG3′    5′ACCCAAAAAGGTGACATGGA3′              184            60                    56              47.5--61.5%B in 4.5 min
  13         5′CATCAGTTTGCCAGTTGTGC3′    5′ACACGGCTTTACCTCCAATG3′              142            60                    59              44.2--58.2%B in 4.5 min
  17         5′TGTATTCACAGAGACTTGGC3′    5′GGATTTACATTATGAAAGTCACAGG3′         172            55                    56              46.7--60.7%B in 4.5 min

###### 

*VEGF-A* PCR conditions

  **Exon**   **Forward primer**     **Reverse primer**      **Size (bp)**   **Temperature (°C)**   **Oven temperature (°C)**   **Buffer concentration (%B)**
  ---------- ---------------------- ---------------------- --------------- ---------------------- --------------------------- -------------------------------
  1          GGGGAGGAAGAGTAGCTCG    GCACCTAAGACGACAGAGGG         324                 60                      66.8                          55.4
  2          CTGTTGGTGGGAGGGAAGTG   AAGGAATTAGGCCATCCACC         224                 65                      63.0                           47
  3          GCTAGCCATCTTTTGTGTCG   TGTTCCCAAAGTGTTACCCC         314                 65                      61.8                          55.1
  4          GGTTGTCCCATCTGGGTATG   TAACCCTGGCACAGATCAGG         210                 65                      60.9                          46.3
  5          TCACCATCTTAACCCTTCCC   ACAGAGGTAGCCAAGAGCCC         161                 65                      60.7                           39
  6          CCTGCCCACCTTACCACTTC   GAGGCTCCAGGGCATTAGAC         188                 65                      60.8                           41
  7          CAGCTGCGGACATGTTAGG    TCGCTCGCTCACTCTCTTTC         313                 65                      59.8                          55.1

[^1]: These authors contributed equally to this work.
